Literature DB >> 10679962

Immunocytochemical analysis of human muscular dystrophy.

C A Sewry1.   

Abstract

Immunocytochemistry is an essential tool for the assessment of muscle biopsies from patients with muscular dystrophy, especially the recessive forms. Antibodies can detect primary defects when there is an alteration in expression, in particular in Xp21 muscular dystrophies, Emery-Dreifuss muscular dystrophy, the limb-girdle dystrophies caused by abnormal expression of the sarcoglycans, and in the form of congenital muscular dystrophy linked to the gene for laminin alpha2. Absence of a protein is easily observed and reduction in expression can be assessed provided adequate controls and baselines are established. Assessment of secondary defects can also be of diagnostic value; they widen the understanding of pathology changes, and are helping in the development of therapeutic strategies. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10679962     DOI: 10.1002/(SICI)1097-0029(20000201/15)48:3/4<142::AID-JEMT3>3.0.CO;2-9

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  7 in total

1.  Paraffin wax embedded muscle is suitable for the diagnosis of muscular dystrophy.

Authors:  C A Sewry
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

2.  From proteins to genes: immunoanalysis in the diagnosis of muscular dystrophies.

Authors:  Rita Barresi
Journal:  Skelet Muscle       Date:  2011-06-24       Impact factor: 4.912

3.  Biodistribution and molecular studies on orally administered nanoparticle-AON complexes encapsulated with alginate aiming at inducing dystrophin rescue in mdx mice.

Authors:  Maria Sofia Falzarano; Chiara Passarelli; Elena Bassi; Marina Fabris; Daniela Perrone; Patrizia Sabatelli; Nadir M Maraldi; Silvia Donà; Rita Selvatici; Paolo Bonaldo; Katia Sparnacci; Michele Laus; Paola Braghetta; Paola Rimessi; Alessandra Ferlini
Journal:  Biomed Res Int       Date:  2013-12-12       Impact factor: 3.411

4.  The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy.

Authors:  Simon Guiraud; Benjamin Edwards; Arran Babbs; Sarah E Squire; Adam Berg; Lee Moir; Matthew J Wood; Kay E Davies
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

5.  Homozygous expression of the myofibrillar myopathy-associated p.W2710X filamin C variant reveals major pathomechanisms of sarcomeric lesion formation.

Authors:  Julia Schuld; Zacharias Orfanos; Frédéric Chevessier; Britta Eggers; Lorena Heil; Julian Uszkoreit; Andreas Unger; Gregor Kirfel; Peter F M van der Ven; Katrin Marcus; Wolfgang A Linke; Christoph S Clemen; Rolf Schröder; Dieter O Fürst
Journal:  Acta Neuropathol Commun       Date:  2020-09-04       Impact factor: 7.801

6.  Duchenne and Becker muscular dystrophy: contribution of a molecular and immunohistochemical analysis in diagnosis in Morocco.

Authors:  Hanane Bellayou; Khalil Hamzi; Mohamed Abdou Rafai; Mehdi Karkouri; Ilham Slassi; Houssine Azeddoug; Sellama Nadifi
Journal:  J Biomed Biotechnol       Date:  2009-05-19

7.  Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice.

Authors:  Elena Bassi; Sofia Falzarano; Marina Fabris; Francesca Gualandi; Luciano Merlini; Gaetano Vattemi; Daniela Perrone; Elena Marchesi; Patrizia Sabatelli; Katia Sparnacci; Michele Laus; Paolo Bonaldo; Paola Rimessi; Paola Braghetta; Alessandra Ferlini
Journal:  J Biomed Biotechnol       Date:  2012-10-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.